Dianthus (DNTH) Gains 18% in the Past Month: Here's Why

Its lead investigational candidate is DNTH103, which is being developed for several autoimmune indications, like generalized Myasthenia Gravis (gMG), multifocal motor neuropathy (MMN) and chronic inflammatory demyelinating polyneuropathy (CIDP). DNTH103 is a monoclonal antibody in clinical development. It is designed to selectively inhibit the active form of the C1s protein, a vital component of the classical complement pathway, which has been clinically validated as a therapeutic target for autoimmune dise ...